Report

1 INTRODUCTION 43
1.1 STUDY OBJECTIVES 43
1.2 MARKET DEFINITION 44
1.2.1 INCLUSIONS & EXCLUSIONS 44
1.3 STUDY SCOPE 46
1.3.1 STUDY SCOPE 46
1.4 YEARS CONSIDERED 47
1.5 CURRENCY CONSIDERED 47
1.6 STAKEHOLDERS 47
1.7 SUMMARY OF CHANGES 48
2 RESEARCH METHODOLOGY 49
2.1 RESEARCH DATA 49
2.1.1 SECONDARY DATA 50
2.1.2 PRIMARY DATA 51
2.2 MARKET ESTIMATION METHODOLOGY 52
2.2.1 INSIGHTS OF PRIMARY EXPERTS 55
2.2.2 TOP-DOWN APPROACH 55
2.3 MARKET GROWTH RATE FORECAST 56
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 58
2.5 RESEARCH ASSUMPTIONS 59
2.6 RESEARCH LIMITATIONS 60
2.7 RISK ASSESSMENT 61
3 EXECUTIVE SUMMARY 62
4 PREMIUM INSIGHTS 67
4.1 BIOMARKERS MARKET OVERVIEW 67
4.2 ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING 68
4.3 BIOMARKERS MARKET SHARE, BY END USER, 2024 69
4.4 BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
5.2.1 MARKET DRIVERS 72
5.2.1.1 Increasing use of biomarkers in drug discovery & development 72
5.2.1.2 Growing importance of companion diagnostics 72
5.2.1.3 Rising prevalence of cancer 73
5.2.1.4 Development of biomarkers for rare diseases 74
5.2.1.5 Increasing funds and grants for biomarker research 75
5.2.1.6 Advancement in omics technologies 76
5.2.2 RESTRAINTS 77
5.2.2.1 High capital investments and extensive timelines for biomarker development 77
5.2.2.2 Disease complexity and heterogeneity 78
5.2.3 OPPORTUNITIES 79
5.2.3.1 Growing preference for personalized medicine and precision oncology 79
5.2.3.2 Enhanced collaboration among healthcare providers and key industry players 79
5.2.3.3 High growth potential of emerging economies 80
5.2.4 CHALLENGES 81
5.2.4.1 Issues associated with quantification & validation of biomarkers 81
5.2.4.2 Complexities associated with data set integration 82
5.2.4.3 Technical issues related to sample collection and storage 82
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 82
5.4 REGULATORY ANALYSIS 83
5.4.1 REGULATORY SCENARIO 83
5.4.1.1 US 83
5.4.1.2 Europe 84
5.4.1.3 Asia Pacific 84
5.4.1.4 Rest of the World 85
5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
5.5 VALUE CHAIN ANALYSIS 91
5.6 TECHNOLOGICAL ANALYSIS 93
5.6.1 KEY TECHNOLOGIES 93
5.6.1.1 Immunoassays 93
5.6.1.1.1 Immunohistochemistry (IHC) 93
5.6.1.1.2 ELISA 94
5.6.1.2 Next-generation Sequencing (NGS) 94
5.6.1.3 Polymerase chain reaction (PCR) 94
5.6.1.4 In situ hybridization 95
5.6.1.5 Microarrays 95
5.6.1.6 Mass Spectrometry 95
5.6.2 COMPLEMENTARY TECHNOLOGIES 96
5.6.2.1 Liquid biopsy 96
5.6.2.2 CRISPR 96
5.6.3 ADJACENT TECHNOLOGIES 96
5.6.3.1 Artificial intelligence (AI) and machine learning (ML) 96
5.6.3.2 Sensors (wearable devices) 96
5.7 PRICING ANALYSIS 97
5.7.1 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER,
2022-2024 97
5.7.2 INDICATIVE SELLING PRICE TREND OF BIOMARKER CONSUMABLES,
BY REGION, 2024 98
5.8 PATENT ANALYSIS 99
5.8.1 METHODOLOGY 99
5.8.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2025 99
5.9 ECOSYSTEM ANALYSIS 103
5.10 KEY CONFERENCES & EVENTS, 2025-2026 104
5.11 PORTER'S FIVE FORCES ANALYSIS 105
5.11.1 INTENSITY OF COMPETITIVE RIVALRY 106
5.11.2 BARGAINING POWER OF SUPPLIERS 106
5.11.3 BARGAINING POWER OF BUYERS 107
5.11.4 THREAT OF SUBSTITUTES 107
5.11.5 THREAT OF NEW ENTRANTS 107
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 108
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 108
5.12.2 BIOMARKERS MARKET: BUYING CRITERIA 109
5.13 INVESTMENT & FUNDING SCENARIO 110
5.14 TRADE DATA ANALYSIS 111
5.14.1 IMPORT SCENARIO: HS CODE 382200, 2020-2024 112
5.14.2 EXPORT SCENARIO: HS CODE 382200, 2020-2024 113
5.15 IMPACT OF AI/GENERATIVE AI ON BIOMARKERS MARKET 114
5.15.1 INTRODUCTION 114
5.15.2 USE CASES 114
5.15.3 FUTURE OF AI IN BIOMARKER ECOSYSTEM 116
5.16 IMPACT OF 2025 US TARIFF ON BIOMARKERS MARKET 116
5.16.1 KEY TARIFF RATES 117
5.16.2 PRICE IMPACT ANALYSIS 118
5.16.3 IMPACT ON COUNTRIES/REGIONS 119
5.16.3.1 US 119
5.16.3.2 Europe 120
5.16.3.3 Asia Pacific 121
5.16.4 IMPACT ON END-USE INDUSTRIES 121
5.16.4.1 Pharmaceutical & biotech companies 122
5.16.4.2 Hospitals & diagnostic laboratories 122
5.16.4.3 Contract research organizations 122
?
6 BIOMARKERS MARKET, BY OFFERING 123
6.1 INTRODUCTION 124
6.2 CONSUMABLES 124
6.2.1 ASSAY KITS 128
6.2.1.1 Growing demand for assay kits in biomarker detection, quantification, and characterization to support growth 128
6.2.2 REAGENTS & CHEMICALS 132
6.2.2.1 Recurrent usage of reagents & chemicals in drug discovery and development to support demand 132
6.2.3 OTHER CONSUMABLES 136
6.3 SERVICES 139
6.3.1 GRADUAL TRANSITION FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING SERVICES TO FUEL MARKET EXPANSION 139
6.4 SOFTWARE 143
6.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET GROWTH 143
7 BIOMARKERS MARKET, BY TYPE 147
7.1 INTRODUCTION 148
7.2 SAFETY BIOMARKERS 148
7.2.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN THERAPEUTIC AREAS TO BOOST MARKET GROWTH 148
7.3 EFFICACY BIOMARKERS 152
7.3.1 PREDICTIVE BIOMARKERS 155
7.3.1.1 Rising applications of biomarkers in personalized medicine to drive market 155
7.3.2 SURROGATE BIOMARKERS 159
7.3.2.1 Ability to serve as reliable indicator in place of clinical endpoints to support market growth 159
7.3.3 PHARMACODYNAMIC BIOMARKERS 163
7.3.3.1 Increasing utilization of pharmacodynamic biomarkers in biomarker and drug development to boost market 163
7.3.4 PROGNOSTIC BIOMARKERS 167
7.3.4.1 Increasing number of clinical trials to support growth of prognostic biomarkers 167
7.4 VALIDATION BIOMARKERS 170
7.4.1 RISING RESEARCH FOR NEW DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH 170
8 BIOMARKERS MARKET, BY RESEARCH AREA 174
8.1 INTRODUCTION 175
8.2 GENOMICS 175
8.2.1 ADVANCEMENTS IN GENOMICS TECHNOLOGIES TO DRIVE SEGMENT GROWTH 175
?
8.3 PROTEOMICS 179
8.3.1 GROWING PATIENT POPULATION WITH CHRONIC DISEASES TO DRIVE DEMAND 179
8.4 METABOLOMICS 183
8.4.1 RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH 183
8.5 OTHER RESEARCH AREAS 186
9 BIOMARKERS MARKET, BY TECHNOLOGY 190
9.1 INTRODUCTION 191
9.2 IMMUNOASSAYS 191
9.2.1 ELISA 195
9.2.1.1 Extensive application of ELISA assays in clinical laboratories to support growth 195
9.2.2 PROTEIN MICROARRAYS 199
9.2.2.1 Quick and cost-effective nature of technology to support growth 199
9.2.3 WESTERN BLOT 203
9.2.3.1 Increasing investments in proteomics research to drive market 203
9.3 NEXT-GENERATION SEQUENCING (NGS) 206
9.3.1 TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO SUPPORT GROWTH 206
9.4 POLYMERASE CHAIN REACTION (PCR) 210
9.4.1 RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET 210
9.5 MASS SPECTROMETRY 214
9.5.1 INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE GROWTH 214
9.6 CHROMATOGRAPHY 217
9.6.1 GROWING UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH 217
9.7 OTHER TECHNOLOGIES 221
10 BIOMARKERS MARKET, BY DISEASE INDICATION 225
10.1 INTRODUCTION 226
10.2 CANCER 226
10.2.1 INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH AND DIAGNOSIS TO DRIVE MARKET 226
10.3 INFECTIOUS DISEASES 231
10.3.1 INCREASING RESEARCH AND GROWING FUNDING TO IDENTIFY BIOMARKERS FOR INFECTIOUS DISEASES TO DRIVE DEMAND 231
10.4 IMMUNOLOGICAL DISORDERS 235
10.4.1 RISING ADOPTION OF ASSAYS FOR AUTOIMMUNE DISEASE DETECTION TO DRIVE MARKET 235
10.5 NEUROLOGICAL DISORDERS 239
10.5.1 WIDE USE OF BIOMARKERS IN DIAGNOSIS AND PRECISION MEDICINE OF NEUROLOGICAL DISORDERS TO SUPPORT GROWTH 239
10.6 CARDIOVASCULAR DISORDERS 243
10.6.1 GROWING PREVALENCE OF CVD TO INCREASE DEMAND FOR CARDIAC BIOMARKERS 243
10.7 OTHER DISEASE INDICATIONS 247
11 BIOMARKERS MARKET, BY APPLICATION 251
11.1 INTRODUCTION 252
11.2 CLINICAL DIAGNOSTICS 252
11.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO SUPPORT DEMAND 252
11.3 DRUG DISCOVERY & DEVELOPMENT 256
11.3.1 INCREASING UTILIZATION OF BIOMARKERS IN DRUG DEVELOPMENT TO SUPPORT GROWTH 256
11.4 PERSONALIZED MEDICINE 260
11.4.1 GROWING PREFERENCE FOR PRECISION THERAPEUTICS TO SUPPORT DEMAND 260
11.5 CLINICAL RESEARCH 264
11.5.1 GROWING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET 264
11.6 OTHER APPLICATIONS 268
12 BIOMARKERS MARKET, BY END USER 272
12.1 INTRODUCTION 273
12.2 PHARMACEUTICAL & BIOTECHNOLOGIES COMPANIES 273
12.2.1 GROWING MARKET STRATEGIES BY KEY PLAYERS TO SUPPORT MARKET GROWTH 273
12.3 HOSPITALS & DIAGNOSTIC LABORATORIES 278
12.3.1 VITAL ROLE OF BIOMARKERS AS BIOLOGICAL INDICATORS IN DIAGNOSIS OF DISEASES TO FUEL MARKET GROWTH 278
12.4 ACADEMIC & RESEARCH INSTITUTES 282
12.4.1 INCREASING FUNDING ACTIVITIES TO DRIVE MARKET 282
12.5 OTHER END USERS 285
13 BIOMARKERS MARKET, BY REGION 289
13.1 INTRODUCTION 290
13.2 NORTH AMERICA 290
13.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA 291
13.2.2 US 297
13.2.2.1 Rising focus on biopharma research to support growth 297
13.2.3 CANADA 302
13.2.3.1 Increasing incidence of cancer to drive biomarkers market growth 302
13.3 EUROPE 307
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 307
13.3.2 GERMANY 313
13.3.2.1 Growth in biopharmaceutical R&D activities to propel growth 313
13.3.3 UK 318
13.3.3.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers 318
13.3.4 FRANCE 323
13.3.4.1 Increasing government investment for proteomics & genomics research to drive growth 323
13.3.5 ITALY 328
13.3.5.1 Increasing developments in life science research to fuel growth 328
13.3.6 SPAIN 332
13.3.6.1 R&D initiatives for personalized medicine to support market growth 332
13.3.7 REST OF EUROPE 337
13.4 ASIA PACIFIC 342
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 342
13.4.2 CHINA 349
13.4.2.1 Rising incidence of CVD to propel market 349
13.4.3 JAPAN 354
13.4.3.1 Strong regulatory guidelines for drug discovery & development to support market growth 354
13.4.4 INDIA 359
13.4.4.1 Favorable scenario for FDI and increasing number of clinical trials to propel market 359
13.4.5 SOUTH KOREA 364
13.4.5.1 Increasing innovations in NGS technologies to support market growth 364
13.4.6 AUSTRALIA 369
13.4.6.1 Increasing demand for diagnostic solutions to propel market 369
13.4.7 REST OF ASIA PACIFIC 373
13.5 LATIN AMERICA 378
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 378
13.5.2 BRAZIL 384
13.5.2.1 Increased government investments in pharmaceutical R&D to drive market 384
13.5.3 MEXICO 388
13.5.3.1 Rising demand for chronic disease treatment to support market growth 388
13.5.4 REST OF LATIN AMERICA 393
13.6 MIDDLE EAST 398
13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 398
13.6.2 GCC COUNTRIES 403
13.6.3 SAUDI ARABIA 407
13.6.3.1 Growing healthcare expenditure to boost market growth 407
13.6.4 UAE 412
13.6.4.1 Increasing collaborative efforts for pharmaceutical R&D to drive growth 412
?
13.6.5 REST OF GCC COUNTRIES 416
13.6.5.1 Other GCC countries include Bahrain, Kuwait, Oman, and Qatar. 416
13.6.6 REST OF MIDDLE EAST 421
13.6.6.1 The Rest of the Middle East includes Egypt, Turkey, Iran, and Iraq. 421
13.7 AFRICA 426
13.7.1 INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET 426
13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 426
14 COMPETITIVE LANDSCAPE 432
14.1 INTRODUCTION 432
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 432
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET 432
14.3 REVENUE ANALYSIS, 2022-2024 436
14.4 MARKET SHARE ANALYSIS, 2024 438
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 441
14.5.1 STARS 442
14.5.2 EMERGING LEADERS 442
14.5.3 PERVASIVE PLAYERS 442
14.5.4 PARTICIPANTS 442
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 444
14.5.5.1 Company footprint 444
14.5.5.2 Region footprint 445
14.5.5.3 Offering footprint 446
14.5.5.4 Technology footprint 448
14.5.5.5 Application footprint 450
14.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024 452
14.6.1 PROGRESSIVE COMPANIES 452
14.6.2 RESPONSIVE COMPANIES 452
14.6.3 DYNAMIC COMPANIES 452
14.6.4 STARTING BLOCKS 452
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 454
14.6.5.1 Detailed list of key startups/SMEs 454
14.6.5.2 Competitive benchmarking of key startups/SMEs 456
14.7 COMPANY VALUATION & FINANCIAL METRICS 457
14.7.1 VALUATION OF KEY PLAYERS 457
14.7.2 FINANCIAL METRICS OF KEY PLAYERS 457
14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 458
14.8.1 BIOMARKER MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF BIOMARKER-BASED ASSAYS 458
?
14.9 COMPETITIVE SCENARIO 459
14.9.1 PRODUCT LAUNCHES & APPROVALS 459
14.9.2 DEALS 460
14.9.3 EXPANSIONS 461
15 COMPANY PROFILES 462
15.1 KEY PLAYERS 462
15.1.1 THERMO FISHER SCIENTIFIC INC. 462
15.1.1.1 Business overview 462
15.1.1.2 Products & services offered 463
15.1.1.3 Recent developments 469
15.1.1.3.1 Product launches & approvals 469
15.1.1.3.2 Deals 470
15.1.1.3.3 Expansions 471
15.1.1.4 MnM view 472
15.1.1.4.1 Right to win 472
15.1.1.4.2 Strategic choices 472
15.1.1.4.3 Weaknesses & competitive threats 472
15.1.2 MERCK KGAA 473
15.1.2.1 Business overview 473
15.1.2.2 Products & services offered 474
15.1.2.3 Recent developments 477
15.1.2.3.1 Deals 477
15.1.2.3.2 Expansions 478
15.1.2.4 MnM view 478
15.1.2.4.1 Right to win 478
15.1.2.4.2 Strategic choices 478
15.1.2.4.3 Weaknesses & competitive threats 478
15.1.3 F. HOFFMANN-LA ROCHE LTD. 479
15.1.3.1 Business overview 479
15.1.3.2 Products & services offered 480
15.1.3.3 Recent developments 482
15.1.3.3.1 Product launches & approvals 482
15.1.3.3.2 Deals 485
15.1.4 QIAGEN 486
15.1.4.1 Business overview 486
15.1.4.2 Products & services offered 487
15.1.4.3 Recent developments 489
15.1.4.3.1 Product launches & approvals 489
15.1.4.3.2 Deals 490
15.1.4.3.3 Expansions 491
?
15.1.5 ABBOTT 492
15.1.5.1 Business overview 492
15.1.5.2 Products & services offered 493
15.1.5.3 Recent developments 495
15.1.5.3.1 Product launches & approvals 495
15.1.5.3.2 Deals 495
15.1.6 AGILENT TECHNOLOGIES, INC. 496
15.1.6.1 Business overview 496
15.1.6.2 Products & services offered 497
15.1.6.3 Recent developments 498
15.1.6.3.1 Product launches & approvals 498
15.1.6.3.2 Deals 499
15.1.7 REVVITY INC. 501
15.1.7.1 Business overview 501
15.1.7.2 Products & services offered 502
15.1.8 CHARLES RIVER LABORATORIES 504
15.1.8.1 Business overview 504
15.1.8.2 Products & services offered 505
15.1.8.3 Recent developments 506
15.1.8.3.1 Deals 506
15.1.9 BIO-RAD LABORATORIES, INC. 507
15.1.9.1 Business overview 507
15.1.9.2 Products & services offered 508
15.1.9.3 Recent developments 510
15.1.9.3.1 Product launches 510
15.1.9.3.2 Deals 510
15.1.10 EUROFINS SCIENTIFIC 511
15.1.10.1 Business overview 511
15.1.10.2 Products & services offered 512
15.1.10.3 Recent developments 513
15.1.10.3.1 Deals 513
15.1.11 BIOMERIEUX 514
15.1.11.1 Business overview 514
15.1.11.2 Products & services offered 515
15.1.11.3 Recent developments 516
15.1.11.3.1 Product launches & approvals 516
15.1.11.3.2 Deals 516
15.1.12 ILLUMINA, INC. 517
15.1.12.1 Business overview 517
15.1.12.2 Products & services offered 519
15.1.12.3 Recent developments 519
15.1.12.3.1 Product launches & approvals 519
15.1.12.3.2 Deals 520
15.1.13 JSR CORPORATION 521
15.1.13.1 Business overview 521
15.1.13.2 Products & services offered 522
15.1.13.3 Recent developments 523
15.1.13.3.1 Deals 523
15.1.14 GUARDANT HEALTH 524
15.1.14.1 Business overview 524
15.1.14.2 Products & services offered 526
15.1.14.3 Recent developments 526
15.1.14.3.1 Product launches & approvals 526
15.1.14.3.2 Deals 527
15.1.15 LABCORP 529
15.1.15.1 Business overview 529
15.1.15.2 Products & services offered 530
15.1.15.3 Recent developments 531
15.1.15.3.1 Product launches 531
15.1.16 QUANTERIX 532
15.1.16.1 Business overview 532
15.1.16.2 Products & services offered 533
15.1.16.3 Recent developments 534
15.1.16.3.1 Product launches 534
15.1.16.3.2 Deals 534
15.1.17 MESO SCALE DIAGNOSTICS, LLC 535
15.1.17.1 Business overview 535
15.1.17.2 Products & services offered 535
15.2 OTHER PLAYERS 537
15.2.1 CELERION 537
15.2.2 STANDARD BIOTOOLS 538
15.2.3 SEBIA 539
15.2.4 BIOAGILYTIX LABS 540
15.2.5 STRESSMARQ BIOSCIENCES INC. 541
15.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC 542
15.2.7 SIGNOSIS 543
15.2.8 SERIMMUNE 544
15.2.9 THERAINDX LIFESCIENCES PVT. LTD. 544
15.2.10 SYNEXA LIFE SCIENCES BV 545
15.2.11 DIATECH PHARMACOGENETICS 546
15.2.12 SINGULEX, INC. 547
15.2.13 R-BIOPHARM AG 548
?
16 APPENDIX 549
16.1 DISCUSSION GUIDE 549
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 555
16.3 CUSTOMIZATION OPTIONS 557
16.4 RELATED REPORTS 558
16.5 AUTHOR DETAILS 559

TABLE 1 BIOMARKERS MARKET: IMPACT ANALYSIS 71
TABLE 2 CANCER INCIDENCE, BY REGION (2040) 74
TABLE 3 BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS, 2022?2024 76
TABLE 4 TIMEFRAME FOR BIOMARKER DEVELOPMENT 78
TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 88
TABLE 8 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 90
TABLE 9 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER,
2022-2024 (USD) 97
TABLE 10 INDICATIVE SELLING PRICE TREND OF BIOMARKER CONSUMABLES, BY REGION, 2024 (USD) 98
TABLE 11 NUMBER OF PATENTS FILED IN BIOMARKERS MARKET, 2014-2025 99
TABLE 12 DETAILED ANALYSIS OF KEY PATENTS IN BIOMARKERS MARKET, 2024-2025 100
TABLE 13 BIOMARKERS MARKET: ECOSYSTEM 103
TABLE 14 BIOMARKERS MARKET: LIST OF CONFERENCES & EVENTS, 2025-2026 104
TABLE 15 BIOMARKERS MARKET: PORTER'S FIVE FORCES ANALYSIS 105
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOMARKER-BASED OFFERINGS 108
TABLE 17 BUYING CRITERIA FOR BIOMARKER PRODUCTS, BY END USER 109
TABLE 18 CANCER BIOMARKER FUNDING BY VARIOUS INSTITUTES/CENTERS
IN US, 2021-2024 111
TABLE 19 IMPORT DATA FOR HS CODE 382200, BY COUNTRY,
2020-2024 (USD THOUSAND) 112
TABLE 20 EXPORT DATA FOR HS CODE 382200, BY COUNTRY,
2020-2024 (USD THOUSAND) 113
TABLE 21 TABLE 1: US-ADJUSTED RECIPROCAL TARIFF RATES 117
TABLE 22 BIOMARKER PRODUCT-RELATED TARIFF REVISIONS 118
TABLE 23 IMPACT ON END-USE APPLICATIONS OF BIOMARKER PRODUCTS 122
TABLE 24 BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 124
TABLE 25 BIOMARKER CONSUMABLES MARKET, BY REGION, 2023-2030 (USD MILLION) 125
TABLE 26 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 125
TABLE 27 EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 126
TABLE 28 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 126
TABLE 29 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 127
TABLE 30 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY REGION,
2023-2030 (USD MILLION) 127
TABLE 31 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 127
TABLE 32 BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION) 128
TABLE 33 BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY REGION,
2023-2030 (USD MILLION) 129
TABLE 34 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS,
BY COUNTRY, 2023-2030 (USD MILLION) 130
TABLE 35 EUROPE: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS,
BY COUNTRY, 2023-2030 (USD MILLION) 130
TABLE 36 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS,
BY COUNTRY, 2023-2030 (USD MILLION) 131
TABLE 37 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS,
BY COUNTRY, 2023-2030 (USD MILLION) 131
TABLE 38 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS,
BY REGION, 2023-2030 (USD MILLION) 131
TABLE 39 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS,
BY COUNTRY, 2023-2030 (USD MILLION) 132
TABLE 40 BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS,
BY REGION, 2023-2030 (USD MILLION) 133
TABLE 41 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023-2030 (USD MILLION) 133
TABLE 42 EUROPE: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS,
BY COUNTRY, 2023-2030 (USD MILLION) 134
TABLE 43 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023-2030 (USD MILLION) 134
TABLE 44 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023-2030 (USD MILLION) 135
TABLE 45 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY REGION, 2023-2030 (USD MILLION) 135
TABLE 46 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023-2030 (USD MILLION) 135
TABLE 47 OTHER BIOMARKER CONSUMABLES MARKET, BY REGION,
2023-2030 (USD MILLION) 136
TABLE 48 NORTH AMERICA: OTHER BIOMARKER CONSUMABLES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 137
TABLE 49 EUROPE: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 137
TABLE 50 ASIA PACIFIC: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 138
TABLE 51 LATIN AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 138
TABLE 52 MIDDLE EAST: OTHER BIOMARKER CONSUMABLES MARKET, BY REGION,
2023-2030 (USD MILLION) 138
TABLE 53 GCC COUNTRIES: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 139
TABLE 54 BIOMARKER SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION) 140
TABLE 55 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 141
TABLE 56 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 141
TABLE 57 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 142
TABLE 58 LATIN AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 142
TABLE 59 MIDDLE EAST: BIOMARKER SERVICES MARKET, BY REGION,
2023-2030 (USD MILLION) 142
TABLE 60 GCC COUNTRIES: BIOMARKER SERVICES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 143
TABLE 61 BIOMARKER SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION) 144
TABLE 62 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 144
TABLE 63 EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 145
TABLE 64 ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 145
TABLE 65 LATIN AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 146
TABLE 66 MIDDLE EAST: BIOMARKER SOFTWARE MARKET, BY REGION,
2023-2030 (USD MILLION) 146
TABLE 67 GCC COUNTRIES: BIOMARKER SOFTWARE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 146
TABLE 68 BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 148
TABLE 69 SAFETY BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION) 149
TABLE 70 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 149
TABLE 71 EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 150
TABLE 72 ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 150
TABLE 73 LATIN AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 151
TABLE 74 MIDDLE EAST: SAFETY BIOMARKERS MARKET, BY REGION,
2023-2030 (USD MILLION) 151
TABLE 75 GCC COUNTRIES: SAFETY BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 151
TABLE 76 EFFICACY BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION) 152
TABLE 77 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 152
TABLE 78 EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 153
TABLE 79 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 153
TABLE 80 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 154
TABLE 81 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY REGION,
2023-2030 (USD MILLION) 154
TABLE 82 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 154
TABLE 83 EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 155
TABLE 84 PREDICTIVE BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION) 156
TABLE 85 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 156
TABLE 86 EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 157
TABLE 87 ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 157
TABLE 88 LATIN AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 158
TABLE 89 MIDDLE EAST: PREDICTIVE BIOMARKERS MARKET, BY REGION,
2023-2030 (USD MILLION) 158
TABLE 90 GCC COUNTRIES: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 158
TABLE 91 SURROGATE BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION) 160
TABLE 92 NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 160
TABLE 93 EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 161
TABLE 94 ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 161
TABLE 95 LATIN AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 162
TABLE 96 MIDDLE EAST: SURROGATE BIOMARKERS MARKET, BY REGION,
2023-2030 (USD MILLION) 162
TABLE 97 GCC COUNTRIES: SURROGATE BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 162
TABLE 98 PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION,
2023-2030 (USD MILLION) 164
TABLE 99 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 164
TABLE 100 EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 165
TABLE 101 ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 165
TABLE 102 LATIN AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 166
TABLE 103 MIDDLE EAST: PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION,
2023-2030 (USD MILLION) 166
TABLE 104 GCC COUNTRIES: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 166
TABLE 105 PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION) 167
TABLE 106 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 168
TABLE 107 EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 168
TABLE 108 ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 169
TABLE 109 LATIN AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 169
TABLE 110 MIDDLE EAST: PROGNOSTIC BIOMARKERS MARKET, BY REGION,
2023-2030 (USD MILLION) 169
TABLE 111 GCC COUNTRIES: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 170
TABLE 112 VALIDATION BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION) 171
TABLE 113 NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 171
TABLE 114 EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 172
TABLE 115 ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 172
TABLE 116 LATIN AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 173
TABLE 117 MIDDLE EAST: VALIDATION BIOMARKERS MARKET, BY REGION,
2023-2030 (USD MILLION) 173
TABLE 118 GCC COUNTRIES: VALIDATION BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 173
TABLE 119 BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 175
TABLE 120 BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2023-2030 (USD MILLION) 176
TABLE 121 NORTH AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY,
2023-2030 (USD MILLION) 176
TABLE 122 EUROPE: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY,
2023-2030 (USD MILLION) 177
TABLE 123 ASIA PACIFIC: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY,
2023-2030 (USD MILLION) 177
TABLE 124 LATIN AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY,
2023-2030 (USD MILLION) 178
TABLE 125 MIDDLE EAST: BIOMARKERS MARKET FOR GENOMICS, BY REGION,
2023-2030 (USD MILLION) 178
TABLE 126 GCC COUNTRIES: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY,
2023-2030 (USD MILLION) 178
TABLE 127 BIOMARKERS MARKET FOR PROTEOMICS, BY REGION,
2023-2030 (USD MILLION) 180
TABLE 128 NORTH AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY,
2023-2030 (USD MILLION) 180
TABLE 129 EUROPE: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY,
2023-2030 (USD MILLION) 181
TABLE 130 ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY,
2023-2030 (USD MILLION) 181
TABLE 131 LATIN AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY,
2023-2030 (USD MILLION) 182
TABLE 132 MIDDLE EAST: BIOMARKERS MARKET FOR PROTEOMICS, BY REGION,
2023-2030 (USD MILLION) 182
TABLE 133 GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY,
2023-2030 (USD MILLION) 182
TABLE 134 BIOMARKERS MARKET FOR METABOLOMICS, BY REGION,
2023-2030 (USD MILLION) 183
TABLE 135 NORTH AMERICA: BIOMARKERS MARKET FOR METABOLOMICS,
BY COUNTRY, 2023-2030 (USD MILLION) 184
TABLE 136 EUROPE: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY,
2023-2030 (USD MILLION) 184
TABLE 137 ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY,
2023-2030 (USD MILLION) 185
TABLE 138 LATIN AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023-2030 (USD MILLION) 185
TABLE 139 MIDDLE EAST: BIOMARKERS MARKET FOR METABOLOMICS, BY REGION,
2023-2030 (USD MILLION) 185
TABLE 140 GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLOMICS,
BY COUNTRY, 2023-2030 (USD MILLION) 186
TABLE 141 BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION,
2023-2030 (USD MILLION) 186
TABLE 142 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS,
BY COUNTRY, 2023-2030 (USD MILLION) 187
TABLE 143 EUROPE: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023-2030 (USD MILLION) 187
TABLE 144 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS,
BY COUNTRY, 2023-2030 (USD MILLION) 188
TABLE 145 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS,
BY COUNTRY, 2023-2030 (USD MILLION) 188
TABLE 146 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS,
BY REGION, 2023-2030 (USD MILLION) 188
TABLE 147 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS,
BY COUNTRY, 2023-2030 (USD MILLION) 189
TABLE 148 BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 191
TABLE 149 BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION,
2023-2030 (USD MILLION) 192
TABLE 150 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2023-2030 (USD MILLION) 193
TABLE 151 EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY,
2023-2030 (USD MILLION) 193
TABLE 152 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY,
2023-2030 (USD MILLION) 194
TABLE 153 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023-2030 (USD MILLION) 194
TABLE 154 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION,
2023-2030 (USD MILLION) 194
TABLE 155 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2023-2030 (USD MILLION) 195
TABLE 156 BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 195
TABLE 157 BIOMARKERS MARKET FOR ELISA, BY REGION, 2023-2030 (USD MILLION) 196
TABLE 158 NORTH AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY,
2023-2030 (USD MILLION) 197
TABLE 159 EUROPE: BIOMARKERS MARKET FOR ELISA, BY COUNTRY,
2023-2030 (USD MILLION) 197
TABLE 160 ASIA PACIFIC: BIOMARKERS MARKET FOR ELISA, BY COUNTRY,
2023-2030 (USD MILLION) 198
TABLE 161 LATIN AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY,
2023-2030 (USD MILLION) 198
TABLE 162 MIDDLE EAST: BIOMARKERS MARKET FOR ELISA, BY REGION,
2023-2030 (USD MILLION) 198
TABLE 163 GCC COUNTRIES: BIOMARKERS MARKET FOR ELISA, BY COUNTRY,
2023-2030 (USD MILLION) 199
TABLE 164 BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY REGION,
2023-2030 (USD MILLION) 200
TABLE 165 NORTH AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS,
BY COUNTRY, 2023-2030 (USD MILLION) 200
TABLE 166 EUROPE: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS,
BY COUNTRY, 2023-2030 (USD MILLION) 201
TABLE 167 ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS,
BY COUNTRY, 2023-2030 (USD MILLION) 201
TABLE 168 LATIN AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS,
BY COUNTRY, 2023-2030 (USD MILLION) 202
TABLE 169 MIDDLE EAST: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS,
BY REGION, 2023-2030 (USD MILLION) 202
TABLE 170 GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS,
BY COUNTRY, 2023-2030 (USD MILLION) 202
TABLE 171 BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION,
2023-2030 (USD MILLION) 203
TABLE 172 NORTH AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT,
BY COUNTRY, 2023-2030 (USD MILLION) 203
TABLE 173 EUROPE: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY,
2023-2030 (USD MILLION) 204
TABLE 174 ASIA PACIFIC: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY,
2023-2030 (USD MILLION) 204
TABLE 175 LATIN AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY,
2023-2030 (USD MILLION) 205
TABLE 176 MIDDLE EAST: BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION,
2023-2030 (USD MILLION) 205
TABLE 177 GCC COUNTRIES: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023-2030 (USD MILLION) 205
TABLE 178 BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION,
2023-2030 (USD MILLION) 207
TABLE 179 NORTH AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION) 207
TABLE 180 EUROPE: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2023-2030 (USD MILLION) 208
TABLE 181 ASIA PACIFIC: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2023-2030 (USD MILLION) 208
TABLE 182 LATIN AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2023-2030 (USD MILLION) 209
TABLE 183 MIDDLE EAST: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING,
BY REGION, 2023-2030 (USD MILLION) 209
TABLE 184 GCC COUNTRIES: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, 2023-2030 (USD MILLION) 209
TABLE 185 BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION,
2023-2030 (USD MILLION) 211
TABLE 186 NORTH AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2023-2030 (USD MILLION) 211
TABLE 187 EUROPE: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2023-2030 (USD MILLION) 212
TABLE 188 ASIA PACIFIC: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2023-2030 (USD MILLION) 212
TABLE 189 LATIN AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2023-2030 (USD MILLION) 213
TABLE 190 MIDDLE EAST: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION,
BY REGION, 2023-2030 (USD MILLION) 213
TABLE 191 GCC COUNTRIES: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2023-2030 (USD MILLION) 213
TABLE 192 BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY REGION,
2023-2030 (USD MILLION) 214
TABLE 193 NORTH AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2023-2030 (USD MILLION) 215
TABLE 194 EUROPE: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY,
2023-2030 (USD MILLION) 215
TABLE 195 ASIA PACIFIC: BIOMARKERS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2023-2030 (USD MILLION) 216
TABLE 196 LATIN AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2023-2030 (USD MILLION) 216
TABLE 197 MIDDLE EAST: BIOMARKERS MARKET FOR MASS SPECTROMETRY,
BY REGION, 2023-2030 (USD MILLION) 216
TABLE 198 GCC COUNTRIES: BIOMARKERS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2023-2030 (USD MILLION) 217
TABLE 199 BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION,
2023-2030 (USD MILLION) 218
TABLE 200 NORTH AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY,
BY COUNTRY, 2023-2030 (USD MILLION) 218
TABLE 201 EUROPE: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY,
2023-2030 (USD MILLION) 219
TABLE 202 ASIA PACIFIC: BIOMARKERS MARKET FOR CHROMATOGRAPHY,
BY COUNTRY, 2023-2030 (USD MILLION) 219
TABLE 203 LATIN AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY,
BY COUNTRY, 2023-2030 (USD MILLION) 220
TABLE 204 MIDDLE EAST: BIOMARKERS MARKET FOR CHROMATOGRAPHY,
BY REGION, 2023-2030 (USD MILLION) 220
TABLE 205 GCC COUNTRIES: BIOMARKERS MARKET FOR CHROMATOGRAPHY,
BY COUNTRY, 2023-2030 (USD MILLION) 220
TABLE 206 BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY REGION,
2023-2030 (USD MILLION) 221
TABLE 207 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2023-2030 (USD MILLION) 222
TABLE 208 EUROPE: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2023-2030 (USD MILLION) 222
TABLE 209 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2023-2030 (USD MILLION) 223
TABLE 210 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2023-2030 (USD MILLION) 223
TABLE 211 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES,
BY REGION, 2023-2030 (USD MILLION) 223
TABLE 212 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2023-2030 (USD MILLION) 224
TABLE 213 BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION) 226
TABLE 214 LIST OF FDA-APPROVED BIOMARKERS FOR CANCER, BY TYPE 227
TABLE 215 BIOMARKERS MARKET FOR CANCER, BY REGION, 2023-2030 (USD MILLION) 228
TABLE 216 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY,
2023-2030 (USD MILLION) 228
TABLE 217 EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY,
2023-2030 (USD MILLION) 229
TABLE 218 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY,
2023-2030 (USD MILLION) 229
TABLE 219 LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY,
2023-2030 (USD MILLION) 230
TABLE 220 MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY REGION,
2023-2030 (USD MILLION) 230
TABLE 221 GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY COUNTRY,
2023-2030 (USD MILLION) 230
TABLE 222 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION,
2023-2030 (USD MILLION) 232
TABLE 223 NORTH AMERICA: INFECTIOUS DISEASES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023-2030 (USD MILLION) 232
TABLE 224 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2023-2030 (USD MILLION) 233
TABLE 225 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023-2030 (USD MILLION) 233
TABLE 226 LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION) 234
TABLE 227 MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION) 234
TABLE 228 GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023-2030 (USD MILLION) 234
TABLE 229 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS 235
TABLE 230 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION,
2023-2030 (USD MILLION) 236
TABLE 231 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 236
TABLE 232 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION) 237
TABLE 233 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 237
TABLE 234 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 238
TABLE 235 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY REGION, 2023-2030 (USD MILLION) 238
TABLE 236 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 238
TABLE 237 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION,
2023-2030 (USD MILLION) 240
TABLE 238 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 240
TABLE 239 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION) 241
TABLE 240 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 241
TABLE 241 LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 242
TABLE 242 MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY REGION, 2023-2030 (USD MILLION) 242
TABLE 243 GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 242
TABLE 244 BIOMARKERS FOR CARDIOVASCULAR DISORDERS 244
TABLE 245 BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION,
2023-2030 (USD MILLION) 244
TABLE 246 NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 244
TABLE 247 EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 245
TABLE 248 ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 245
TABLE 249 LATIN AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 246
TABLE 250 MIDDLE EAST: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS,
BY REGION, 2023-2030 (USD MILLION) 246
TABLE 251 GCC COUNTRIES: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 246
TABLE 252 BIOMARKERS FOR RENAL DISORDERS 247
TABLE 253 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION,
2023-2030 (USD MILLION) 248
TABLE 254 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2023-2030 (USD MILLION) 248
TABLE 255 EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2023-2030 (USD MILLION) 249
TABLE 256 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2023-2030 (USD MILLION) 249
TABLE 257 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2023-2030 (USD MILLION) 250
TABLE 258 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS,
BY REGION, 2023-2030 (USD MILLION) 250
TABLE 259 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2023-2030 (USD MILLION) 250
TABLE 260 BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 252
TABLE 261 BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION,
2023-2030 (USD MILLION) 253
TABLE 262 NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 253
TABLE 263 EUROPE: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 254
TABLE 264 ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 254
TABLE 265 LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 255
TABLE 266 MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS,
BY REGION, 2023-2030 (USD MILLION) 255
TABLE 267 GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS,
BY COUNTRY, 2023-2030 (USD MILLION) 255
TABLE 268 BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023-2030 (USD MILLION) 257
TABLE 269 NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION) 257
TABLE 270 EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT,
BY COUNTRY, 2023-2030 (USD MILLION) 258
TABLE 271 ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT,
BY COUNTRY, 2023-2030 (USD MILLION) 258
TABLE 272 LATIN AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION) 259
TABLE 273 MIDDLE EAST: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023-2030 (USD MILLION) 259
TABLE 274 GCC COUNTRIES: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION) 259
TABLE 275 LIST OF KEY PERSONALIZED MEDICINE AND RELEVANT BIOMARKERS 260
TABLE 276 BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION,
2023-2030 (USD MILLION) 261
TABLE 277 NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2023-2030 (USD MILLION) 261
TABLE 278 EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023-2030 (USD MILLION) 262
TABLE 279 ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2023-2030 (USD MILLION) 262
TABLE 280 LATIN AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2023-2030 (USD MILLION) 263
TABLE 281 MIDDLE EAST: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE,
BY REGION, 2023-2030 (USD MILLION) 263
TABLE 282 GCC COUNTRIES: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2023-2030 (USD MILLION) 263
TABLE 283 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES, BY LOCATION 264
TABLE 284 BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION,
2023-2030 (USD MILLION) 265
TABLE 285 NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023-2030 (USD MILLION) 265
TABLE 286 EUROPE: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY,
2023-2030 (USD MILLION) 266
TABLE 287 ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023-2030 (USD MILLION) 266
TABLE 288 LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023-2030 (USD MILLION) 267
TABLE 289 MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2023-2030 (USD MILLION) 267
TABLE 290 GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023-2030 (USD MILLION) 267
TABLE 291 BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION,
2023-2030 (USD MILLION) 268
TABLE 292 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023-2030 (USD MILLION) 269
TABLE 293 EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2023-2030 (USD MILLION) 269
TABLE 294 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION) 270
TABLE 295 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION) 270
TABLE 296 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION) 270
TABLE 297 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION) 271
TABLE 298 BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 273
TABLE 299 PHARMA & BIOTECH SECTOR: RECENT DEVELOPMENTS 274
TABLE 300 BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION) 275
TABLE 301 NORTH AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION) 275
TABLE 302 EUROPE: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION) 276
TABLE 303 ASIA PACIFIC: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION) 276
TABLE 304 LATIN AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION) 277
TABLE 305 MIDDLE EAST: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION) 277
TABLE 306 GCC COUNTRIES: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION) 277
TABLE 307 BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023-2030 (USD MILLION) 279
TABLE 308 NORTH AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION) 279
TABLE 309 EUROPE: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION) 280
TABLE 310 ASIA PACIFIC: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION) 280
TABLE 311 LATIN AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION) 281
TABLE 312 MIDDLE EAST: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023-2030 (USD MILLION) 281
TABLE 313 GCC COUNTRIES: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION) 281
TABLE 314 BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION) 282
TABLE 315 NORTH AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION) 283
TABLE 316 EUROPE: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY COUNTRY, 2023-2030 (USD MILLION) 283
TABLE 317 ASIA PACIFIC: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY COUNTRY, 2023-2030 (USD MILLION) 284
TABLE 318 LATIN AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION) 284
TABLE 319 MIDDLE EAST: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION) 284
TABLE 320 GCC COUNTRIES: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION) 285
TABLE 321 BIOMARKERS MARKET FOR OTHER END USERS, BY REGION,
2023-2030 (USD MILLION) 286
TABLE 322 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER END USERS,
BY COUNTRY, 2023-2030 (USD MILLION) 286
TABLE 323 EUROPE: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY,
2023-2030 (USD MILLION) 287
TABLE 324 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION) 287
TABLE 325 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION) 288
TABLE 326 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER END USERS, BY REGION,
2023-2030 (USD MILLION) 288
TABLE 327 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION) 288
TABLE 328 BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION) 290
TABLE 329 NORTH AMERICA: KEY MACROINDICATORS 292
TABLE 330 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 293
TABLE 331 NORTH AMERICA: BIOMARKERS MARKET, BY OFFERING,
2023-2030 (USD MILLION) 293
TABLE 332 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 293
TABLE 333 NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 294
TABLE 334 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 294
TABLE 335 NORTH AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA,
2023-2030 (USD MILLION) 294
TABLE 336 NORTH AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 295

TABLE 337 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY TYPE, 2023-2030 (USD MILLION) 295
TABLE 338 NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 296
TABLE 339 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 296
TABLE 340 NORTH AMERICA: BIOMARKERS MARKET, BY END USER,
2023-2030 (USD MILLION) 297
TABLE 341 US: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 298
TABLE 342 US: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION) 298
TABLE 343 US: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 299
TABLE 344 US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 299
TABLE 345 US: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 299
TABLE 346 US: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 300
TABLE 347 US: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 300
TABLE 348 US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION) 301
TABLE 349 US: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 301
TABLE 350 US: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 302
TABLE 351 CANADA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 303
TABLE 352 CANADA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 303
TABLE 353 CANADA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 303
TABLE 354 CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 304
TABLE 355 CANADA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 304
TABLE 356 CANADA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 305
TABLE 357 CANADA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 305
TABLE 358 CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 306
TABLE 359 CANADA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 306
TABLE 360 CANADA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 307
TABLE 361 EUROPE: KEY MACROINDICATORS 308
TABLE 362 EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 308
TABLE 363 EUROPE: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 309
TABLE 364 EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 309
TABLE 365 EUROPE: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 309
TABLE 366 EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 310
TABLE 367 EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 310
TABLE 368 EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 311
TABLE 369 EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 311
TABLE 370 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 312
TABLE 371 EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 312
TABLE 372 EUROPE: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 313
TABLE 373 GERMANY: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 314
TABLE 374 GERMANY: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 314
TABLE 375 GERMANY: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 314
TABLE 376 GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 315
TABLE 377 GERMANY: BIOMARKERS MARKET, BY RESEARCH AREA,
2023-2030 (USD MILLION) 315
TABLE 378 GERMANY: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 316
TABLE 379 GERMANY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 316
TABLE 380 GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 317
TABLE 381 GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 317
TABLE 382 GERMANY: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 318
TABLE 383 UK: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 319
TABLE 384 UK: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION) 319
TABLE 385 UK: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 319
TABLE 386 UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 320
TABLE 387 UK: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 320
TABLE 388 UK: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 321
TABLE 389 UK: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 321
TABLE 390 UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION) 322
TABLE 391 UK: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 322
TABLE 392 UK: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 323
TABLE 393 FRANCE: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 324
TABLE 394 FRANCE: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 324
TABLE 395 FRANCE: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 324
TABLE 396 FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 325
TABLE 397 FRANCE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 325
TABLE 398 FRANCE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 326
TABLE 399 FRANCE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 326
TABLE 400 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 327
TABLE 401 FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 327
TABLE 402 FRANCE: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 328
TABLE 403 ITALY: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 328
TABLE 404 ITALY: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION) 329
TABLE 405 ITALY: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 329
TABLE 406 ITALY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 329
TABLE 407 ITALY: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 330
TABLE 408 ITALY: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 330
TABLE 409 ITALY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 331
TABLE 410 ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 331
TABLE 411 ITALY: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 332
TABLE 412 ITALY: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 332
TABLE 413 SPAIN: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 333
TABLE 414 SPAIN: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 333
TABLE 415 SPAIN: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 334
TABLE 416 SPAIN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 334
TABLE 417 SPAIN: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 334
TABLE 418 SPAIN: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 335
TABLE 419 SPAIN: BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY TYPE, 2023-2030 (USD MILLION) 335
TABLE 420 SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 336
TABLE 421 SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 336
TABLE 422 SPAIN: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 337
TABLE 423 REST OF EUROPE: BIOMARKERS MARKET, BY OFFERING,
2023-2030 (USD MILLION) 338
TABLE 424 REST OF EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 338
TABLE 425 REST OF EUROPE: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 338
TABLE 426 REST OF EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 339
TABLE 427 REST OF EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA,
2023-2030 (USD MILLION) 339
TABLE 428 REST OF EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 340
TABLE 429 REST OF EUROPE: BIOMARKERS MARKET BY IMMUNOASSAYS,
BY TYPE, 2023-2030 (USD MILLION) 340
TABLE 430 REST OF EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 341
TABLE 431 REST OF EUROPE: BIOMARKERS MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 341
TABLE 432 REST OF EUROPE: BIOMARKERS MARKET, BY END USER,
2023-2030 (USD MILLION) 342
TABLE 433 ASIA PACIFIC: KEY MACROINDICATORS 343
TABLE 434 ASIA PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 345
TABLE 435 ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 345
TABLE 436 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 345
TABLE 437 ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 346
TABLE 438 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 346
TABLE 439 ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA,
2023-2030 (USD MILLION) 346
TABLE 440 ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 347
TABLE 441 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 347
TABLE 442 ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 348
TABLE 443 ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 348
TABLE 444 ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 349
TABLE 445 CHINA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 350
TABLE 446 CHINA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 350
TABLE 447 CHINA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 350
TABLE 448 CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 351
TABLE 449 CHINA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 351
TABLE 450 CHINA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 352
TABLE 451 CHINA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 352
TABLE 452 CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 353
TABLE 453 CHINA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 353
TABLE 454 CHINA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 354
TABLE 455 JAPAN: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 355
TABLE 456 JAPAN: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 355
TABLE 457 JAPAN: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 356
TABLE 458 JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 356
TABLE 459 JAPAN: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 356
TABLE 460 JAPAN: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 357
TABLE 461 JAPAN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 357
TABLE 462 JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 358
TABLE 463 JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 358
TABLE 464 JAPAN: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 359
TABLE 465 INDIA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 360
TABLE 466 INDIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION) 360
TABLE 467 INDIA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 360
TABLE 468 INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 361
TABLE 469 INDIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 361
TABLE 470 INDIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 362
TABLE 471 INDIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 362
TABLE 472 INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 363
TABLE 473 INDIA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 363
TABLE 474 INDIA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 364
TABLE 475 SOUTH KOREA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 365
TABLE 476 SOUTH KOREA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 365
TABLE 477 SOUTH KOREA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 365
TABLE 478 SOUTH KOREA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 366
TABLE 479 SOUTH KOREA: BIOMARKERS MARKET, BY RESEARCH AREA,
2023-2030 (USD MILLION) 366
TABLE 480 SOUTH KOREA: BIOMARKERS MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 367
TABLE 481 SOUTH KOREA: BIOMARKERS MARKET BY IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 367
TABLE 482 SOUTH KOREA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 368
TABLE 483 SOUTH KOREA: BIOMARKERS MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 368
TABLE 484 SOUTH KOREA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 369
TABLE 485 AUSTRALIA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 369
TABLE 486 AUSTRALIA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 370
TABLE 487 AUSTRALIA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 370
TABLE 488 AUSTRALIA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 370
TABLE 489 AUSTRALIA: BIOMARKERS MARKET, BY RESEARCH AREA,
2023-2030 (USD MILLION) 371
TABLE 490 AUSTRALIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 371
TABLE 491 AUSTRALIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 372
TABLE 492 AUSTRALIA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 372
TABLE 493 AUSTRALIA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 373
TABLE 494 AUSTRALIA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 373
TABLE 495 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING,
2023-2030 (USD MILLION) 374
TABLE 496 REST OF ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 374
TABLE 497 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 375
TABLE 498 REST OF ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 375
TABLE 499 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA,
2023-2030 (USD MILLION) 375
TABLE 500 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 376
TABLE 501 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY TYPE, 2023-2030 (USD MILLION) 376
TABLE 502 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 377
TABLE 503 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 377
TABLE 504 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY END USER,
2023-2030 (USD MILLION) 378
TABLE 505 LATIN AMERICA: KEY MACROINDICATORS 379
TABLE 506 LATIN AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 379
TABLE 507 LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING,
2023-2030 (USD MILLION) 380
TABLE 508 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 380
TABLE 509 LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 380
TABLE 510 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 381
TABLE 511 LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA,
2023-2030 (USD MILLION) 381
TABLE 512 LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 382
TABLE 513 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY TYPE, 2023-2030 (USD MILLION) 382
TABLE 514 LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 383
TABLE 515 LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 383
TABLE 516 LATIN AMERICA: BIOMARKERS MARKET, BY END USER,
2023-2030 (USD MILLION) 384
TABLE 517 BRAZIL: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 384
TABLE 518 BRAZIL: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 385
TABLE 519 BRAZIL: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 385
TABLE 520 BRAZIL: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 385
TABLE 521 BRAZIL: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 386
TABLE 522 BRAZIL: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 386
TABLE 523 BRAZIL: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 387
TABLE 524 BRAZIL: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 387
TABLE 525 BRAZIL: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 388
TABLE 526 BRAZIL: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 388
TABLE 527 MEXICO: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 389
TABLE 528 MEXICO: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 389
TABLE 529 MEXICO: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 389
TABLE 530 MEXICO: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 390
TABLE 531 MEXICO: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 390
TABLE 532 MEXICO: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 391
TABLE 533 MEXICO: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 391
TABLE 534 MEXICO: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 392
TABLE 535 MEXICO: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 392
TABLE 536 MEXICO: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 393
TABLE 537 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING,
2023-2030 (USD MILLION) 394
TABLE 538 REST OF LATIN AMERICA: BIOMARKER CONSUMABLES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 394
TABLE 539 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 394
TABLE 540 REST OF LATIN AMERICA: EFFICACY BIOMARKERS MARKET,
BY TYPE, 2023-2030 (USD MILLION) 395
TABLE 541 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA,
2023-2030 (USD MILLION) 395
TABLE 542 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 396
TABLE 543 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY TYPE, 2023-2030 (USD MILLION) 396
TABLE 544 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 397
TABLE 545 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 397
TABLE 546 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY END USER,
2023-2030 (USD MILLION) 398
TABLE 547 MIDDLE EAST: KEY MACROINDICATORS 399
TABLE 548 MIDDLE EAST: BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION) 399
TABLE 549 MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 399
TABLE 550 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 400
TABLE 551 MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 400
TABLE 552 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 400
TABLE 553 MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA,
2023-2030 (USD MILLION) 401
TABLE 554 MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 401
TABLE 555 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 401
TABLE 556 MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 402
TABLE 557 MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 402
TABLE 558 MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 403
TABLE 559 GCC COUNTRIES: BIOMARKERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 403
TABLE 560 GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING,
2023-2030 (USD MILLION) 404
TABLE 561 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 404
TABLE 562 GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 404
TABLE 563 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 405
TABLE 564 GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA,
2023-2030 (USD MILLION) 405
TABLE 565 GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 405
TABLE 566 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 406
TABLE 567 GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 406
TABLE 568 GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 407
TABLE 569 GCC COUNTRIES: BIOMARKERS MARKET, BY END USER,
2023-2030 (USD MILLION) 407
TABLE 570 SAUDI ARABIA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 408
TABLE 571 SAUDI ARABIA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 408
TABLE 572 SAUDI ARABIA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 409
TABLE 573 SAUDI ARABIA: EFFICACY BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 409
TABLE 574 SAUDI ARABIA: BIOMARKERS MARKET, BY RESEARCH AREA,
2023-2030 (USD MILLION) 409
TABLE 575 SAUDI ARABIA: BIOMARKERS MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 410
TABLE 576 SAUDI ARABIA: BIOMARKERS MARKET BY IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 410
TABLE 577 SAUDI ARABIA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 411
TABLE 578 SAUDI ARABIA: BIOMARKERS MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 411
TABLE 579 SAUDI ARABIA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 412
TABLE 580 UAE: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 413
TABLE 581 UAE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION) 413
TABLE 582 UAE: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 413
TABLE 583 UAE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 414
TABLE 584 UAE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 414
TABLE 585 UAE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 414
TABLE 586 UAE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 415
TABLE 587 UAE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION) 415
TABLE 588 UAE: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 415
TABLE 589 UAE: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 416
TABLE 590 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING,
2023-2030 (USD MILLION) 417
TABLE 591 REST OF GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 417
TABLE 592 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 417
TABLE 593 REST OF GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 418
TABLE 594 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA,
2023-2030 (USD MILLION) 418
TABLE 595 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 419
TABLE 596 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY TYPE, 2023-2030 (USD MILLION) 419
TABLE 597 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION) 420
TABLE 598 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 420
TABLE 599 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY END USER,
2023-2030 (USD MILLION) 421
TABLE 600 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING,
2023-2030 (USD MILLION) 422
TABLE 601 REST OF MIDDLE EAST: BIOMARKER CONSUMABLES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 422
TABLE 602 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 422
TABLE 603 REST OF MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 423
TABLE 604 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA,
2023-2030 (USD MILLION) 423
TABLE 605 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY,
2023-2030 (USD MILLION) 424
TABLE 606 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS,
BY TYPE, 2023-2030 (USD MILLION) 424
TABLE 607 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 425
TABLE 608 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 425
TABLE 609 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY END USER,
2023-2030 (USD MILLION) 426
TABLE 610 AFRICA: KEY MACROINDICATORS 427
TABLE 611 AFRICA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION) 427
TABLE 612 AFRICA: BIOMARKER CONSUMABLES MARKET, BY TYPE,
2023-2030 (USD MILLION) 428
TABLE 613 AFRICA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 428
TABLE 614 AFRICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 428
TABLE 615 AFRICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION) 429
TABLE 616 AFRICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION) 429
TABLE 617 AFRICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,
2023-2030 (USD MILLION) 429
TABLE 618 AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION,
2023-2030 (USD MILLION) 430
TABLE 619 AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 430
TABLE 620 AFRICA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION) 431
TABLE 621 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET 433
TABLE 622 BIOMARKERS MARKET: DEGREE OF COMPETITION 439
TABLE 623 BIOMARKERS MARKET: REGION FOOTPRINT 445
TABLE 624 BIOMARKERS MARKET: OFFERING FOOTPRINT 446
TABLE 625 BIOMARKERS MARKET: TECHNOLOGY FOOTPRINT 448
TABLE 626 BIOMARKERS MARKET: APPLICATION FOOTPRINT 450
TABLE 627 BIOMARKERS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 454
TABLE 628 BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES PLAYERS 456
TABLE 629 BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022-MAY 2025 459
TABLE 630 BIOMARKERS MARKET: DEALS, JANUARY 2022-MAY 2025 460
TABLE 631 BIOMARKERS MARKET: EXPANSIONS, JANUARY 2022-MAY 2025 461
TABLE 632 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 462
TABLE 633 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED 463
TABLE 634 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022-APRIL 2025 469
TABLE 635 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-APRIL 2025 470
TABLE 636 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022-APRIL 2025 471
TABLE 637 MERCK KGAA: BUSINESS OVERVIEW 473
TABLE 638 MERCK KGAA OFFERINGS: PRODUCTS & SERVICES OFFERED 474
TABLE 639 MERCK KGAA: DEALS, JANUARY 2022-APRIL 2025 477
TABLE 640 MERCK KGAA: EXPANSIONS, JANUARY 2022-APRIL 2025 478
TABLE 641 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 479
TABLE 642 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED 480
TABLE 643 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022-APRIL 2025 482
TABLE 644 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022-APRIL 2025 485
TABLE 645 QIAGEN: BUSINESS OVERVIEW 486
TABLE 646 QIAGEN: PRODUCTS & SERVICES OFFERED 487
TABLE 647 QIAGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-APRIL 2025 489
TABLE 648 QIAGEN: DEALS, JANUARY 2022-APRIL 2025 490
TABLE 649 QIAGEN: EXPANSIONS, JANUARY 2022-APRIL 2025 491
TABLE 650 ABBOTT: BUSINESS OVERVIEW 492
TABLE 651 ABBOTT: PRODUCTS & SERVICES OFFERED 493
TABLE 652 ABBOTT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022�APRIL 2025 495
TABLE 653 ABBOTT: DEALS, JANUARY 2022�APRIL 2025 495
TABLE 654 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 496
TABLE 655 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED 497
TABLE 656 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022�APRIL 2025 498
TABLE 657 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022�APRIL 2025 499
TABLE 658 REVVITY INC.: BUSINESS OVERVIEW 501
TABLE 659 REVVITY INC.: PRODUCTS & SERVICES OFFERED 502
TABLE 660 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 504
TABLE 661 CHARLES RIVER LABORATORIES: PRODUCTS & SERVICES OFFERED 505
TABLE 662 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022�APRIL 2025 506
TABLE 663 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 507
TABLE 664 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED 508
TABLE 665 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022�APRIL 2025 510
TABLE 666 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022�APRIL 2025 510
TABLE 667 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 511
TABLE 668 EUROFINS SCIENTIFIC: PRODUCTS & SERVICES OFFERED 512
TABLE 669 EUROFINS SCIENTIFIC: DEALS, JANUARY 2022�APRIL 2025 513
TABLE 670 BIOMERIEUX: BUSINESS OVERVIEW 514
TABLE 671 BIOMERIEUX: PRODUCTS & SERVICES OFFERED 515
TABLE 672 BIOMERIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-APRIL 2025 516
TABLE 673 BIOMERIEUX: DEALS, JANUARY 2022�APRIL 2025 516
TABLE 674 ILLUMINA, INC.: BUSINESS OVERVIEW 517
TABLE 675 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED 519
TABLE 676 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-APRIL 2025 519
TABLE 677 ILLUMINA, INC.: DEALS, JANUARY 2022�APRIL 2025 520
TABLE 678 JSR CORPORATION: BUSINESS OVERVIEW 521
TABLE 679 JSR CORPORATION: PRODUCTS & SERVICES OFFERED 522
TABLE 680 JSR CORPORATION: DEALS, JANUARY 2022�APRIL 2025 523
TABLE 681 GUARDANT HEALTH: BUSINESS OVERVIEW 524
TABLE 682 GUARDANT HEALTH: PRODUCTS & SERVICES OFFERED 526
TABLE 683 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022-APRIL 2025 526
TABLE 684 GUARDANT HEALTH: DEALS, JANUARY 2022�APRIL 2025 527
TABLE 685 LABCORP: BUSINESS OVERVIEW 529
TABLE 686 LABCORP: PRODUCTS & SERVICES OFFERED 530
TABLE 687 LABCORP: PRODUCT LAUNCHES, JANUARY 2022�APRIL 2025 531
TABLE 688 QUANTERIX: BUSINESS OVERVIEW 532
TABLE 689 QUANTERIX: PRODUCTS & SERVICES OFFERED 533
TABLE 690 QUANTERIX: PRODUCT LAUNCHES, JANUARY 2022�APRIL 2025 534
TABLE 691 QUANTERIX: DEALS, JANUARY 2022�APRIL 2025 534
TABLE 692 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW 535
TABLE 693 MESO SCALE DIAGNOSTICS, LLC: PRODUCTS & SERVICES OFFERED 535
TABLE 694 CELERION: COMPANY OVERVIEW 537
TABLE 695 STANDARD BIOTOOLS: COMPANY OVERVIEW 538
TABLE 696 SEBIA: COMPANY OVERVIEW 539
TABLE 697 BIOAGILYTIX LABS: COMPANY OVERVIEW 540
TABLE 698 STRESSMARQ BIOSCIENCES INC.: COMPANY OVERVIEW 541
TABLE 699 NORTHEAST BIOANALYTICAL LABORATORIES LLC: BUSINESS OVERVIEW 542
TABLE 700 SIGNOSIS: BUSINESS OVERVIEW 543
TABLE 701 SERIMMUNE: BUSINESS OVERVIEW 544
TABLE 702 THERAINDX LIFESCIENCES PVT. LTD.: BUSINESS OVERVIEW 544
TABLE 703 SYNEXA LIFE SCIENCES BV: BUSINESS OVERVIEW 545
TABLE 704 DIATECH PHARMACOGENETICS: BUSINESS OVERVIEW 546
TABLE 705 SINGULEX, INC.: BUSINESS OVERVIEW 547
TABLE 706 R-BIOPHARM AG: BUSINESS OVERVIEW 548